

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known		
				Application Number	10/698,072	
				Filing Date	October 29, 2003	
				First Named Inventor	Cynthia B. Robinson	
				Art Unit	1617	
				Examiner Name	Kevin J. Capps	
Sheet	1	Of	2	Attorney Docket Number		30775-721.201

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
✓	1.	US 2004/0067920	04/08/2004	LEONARD, et al.	
	2.	US 2004/0082522	04/29/2004	NYCE	
	3.	US 2005/0113317	05/26/2005	ROBINSON et al.	
	4.	US 4,501,729	02/26/1985	BOUCHER, et al.	
	5.	US 4,956,355	09/11/1990	PRENDERGAST	
✓	6.	US 6,511,960	01/28/2003	LEZDEY, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² - Number ³ - Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
	7	BE 866,622 (in Belgian with English abstract)	11/03/1978	Cairns et al.		
✓	8.	EP 429,187	05/29/1991	Bourke et al.		
	9.	UK 2,240,472	07/08/1991	MASTERSON		
	10.	WO 1991/04030 A1	04/04/1991	DAYNES et al.		
	11.	WO 1996/25935 A1	08/29/1996	Nyce		
	12.	WO 1997/48367 A3	02/05/1998	ROOK et al.		
	13.	WO 1998/03180 A3	06/04/1998	FERGUSON et al.		
	14.	WO 2000/54763 A3	09/07/2001	PARASRAMPURIA et al.		
	15.	WO 2002/085296 A3	04/03/2003	NYCE		
	16.	WO 2004/014293 A3	09/23/2004	NYCE et al.		

Examiner Signature	<i>Kevin J. Capps</i>	Date Considered	7/14/02
--------------------	-----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

3142875_1.DOC


Attorney Docket No. 30775-721.201

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/698,072
				Filing Date	October 29, 2003
				First Named Inventor	Cynthia B. Robinson
				Art Unit	1617
				Examiner Name	Kevin J. Capps
Sheet	2	Of	2	Attorney Docket Number	30775-721.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
u	17.	Abou-Gharbia, et al. Synthesis of dehydroepiandrosterone sulfatide and 16 alpha-halogenated steroids. J. Pharm. Sci. 1981; 70:1154-1157	
	18.	Ishihara et al. Gas Chromatographic Determination of Degradation Products and Stability of Dehydroepiandrosterone Sulfate in Aqueous Solution. Drug Development and Industrial Pharmacy. 1979; 5(9): 263-275.	
	19.	Merck Index Monograph No. 7710. 11th Ed. Merck & Co. 1989;1221.	

UNPUBLISHED PATENT APPLICATIONS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
✓	20.	LEONARD, et al. US Patent Application No. 10/462,927, entitled "Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof," filed June 17, 2003. (WSGR Reference No. 30775-722.201)	

Examiner Signature		Date Considered	7/14/07
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.


3142875_1.DOC

Attorney Docket No. 30775-721.201

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/698,072
				Filing Date	October 29, 2003
				First Named Inventor	Cynthia B. Robinson
				Art Unit	1617
				Examiner Name	Kevin J. Capps
Sheet	1	Of	2	Attorney Docket Number	30775-721.201

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US 2002/0032160	03/14/2002	Nyce	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² - Number ³ - Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵

Examiner Signature		Date Considered	7/1/07
--------------------	---	-----------------	--------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST .3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FBES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/698,072
				Filing Date	October 29, 2003
				First Named Inventor	Cynthia B. Robinson
				Art Unit	1617
				Examiner Name	Kevin J. Capps
Sheet	2	Of	2	Attorney Docket Number	30775-721.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	2.	CRETICOS, P. S. Managing asthma in adults. Am J Manag Care. 2000; 6(17 Suppl):S940-63.	

Examiner Signature		Date Considered	7/14/07
--------------------	---	-----------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

3013195_1.DOC

Attorney Docket No. 30775-721.201



Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1001</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	10/698,072
				Filing Date	October 29, 2003
				First Named Inventor	Cynthia B. Robinson
				Art Unit	1617
				Examiner Name	San Ming R. Hui
Sheet	1	of	1	Attorney Docket Number	30775-721.201

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET NO.

02486.0073.NPUS01

APPLICATION NO.

10/698,072

APPLICANT


Cynthia B. Robinson, et al.

FILING DATE

October 29, 2003

GROUP

1644



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
UR	1.	3,419,578	Dec. 1968	Fitzmaurice et al.			
	2.	3,957,965	May 1976	Hartley et al.			
	3.	4,393,066	Jul. 1983	Garrett et al.			
	4.	4,474,787	Oct. 1984	Caims et al.			
	5.	4,499,064	Feb. 1985	Shive			
	6.	4,575,498	Mar. 1986	Holmes et al.			
	7.	4,628,052	Dec. 1986	Peat			
	8.	4,760,072	Jul. 1988	Brown et al.			
	9.	4,849,427	Jul. 1989	Nassim et al.			
	10.	4,918,078	Apr. 1990	Brown et al.			
	11.	4,920,115	Apr. 1990	Nestler et al.			
	12.	4,931,441	Jun. 1990	Lawrence			
	13.	4,935,244	Jun. 1990	Clark			
	14.	4,985,443	Jan. 1991	Montes			
	15.	5,021,417	Jun. 1991	Prost			
	16.	5,059,595	Oct. 1991	Le Grazie			
	17.	5,077,284	Dec. 1991	Loria et al.			
	18.	5,110,810	May 1992	Eich et al.			
	19.	5,118,505	Jun. 1992	Költringer			
	20.	5,162,198	Nov. 1992	Eich et al.			
	21.	5,173,488	Dec. 1992	Haeger			
	22.	5,177,076	Jan. 1993	Nijkerk et al.			
	23.	5,266,312	Nov. 1993	Leung et al.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Chapman 7/14/02

<p align="center">LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i></p> <p align="center">PTO FORM 1449</p>	<p>ATTY. DOCKET NO. 02486.0073.NPUS01</p>	<p>APPLICATION NO. 10/698,072</p>
	<p>APPLICANT Cynthia B. Robinson, et al.</p>	
	<p>FILING DATE October 29, 2003</p>	<p>GROUP 1644</p>

24.	5,270,305	Dec. 1993	Palmer				
25.	5,347,005	Sep. 1994	Mueller et al				
26.	5,407,684	Apr. 1995	Loria et al.				
27.	5,407,927	Apr. 1995	Morales et al.				
28.	5,489,581	Feb. 1996	Daynes et al.				
29.	5,527,789	Jun. 1996	Nyce				
30.	5,532,230	Jul. 1996	Daynes et al.				
31.	5,538,734	Jul. 1998	Le Grazie				
32.	5,583,126	Dec. 1996	Daynes et al.				
33.	5,610,140	Mar. 1997	Goodfellow et al.				
34.	5,635,496	Jun. 1997	Daynes et al.				
35.	5,660,835	Aug. 1997	Nyce				
36.	5,686,438	Nov. 1997	Daynes et al.				
37.	5,703,063	Dec. 1997	Chasalow, et al.				
38.	5,767,278	Jun. 1998	Gaeta et al.				
39.	5,811,418	Sep. 1998	Daynes et al.				
40.	5,859,000	Jan. 1999	Dowell et al.				
41.	5,861,391	Jan. 1999	Yen et al.				
42.	5,948,434	Sep. 1999	Labrie				
43.	6,087,351	Jul. 2000	Nyce				
44.	6,093,706	Jul. 2000	Zeligs				
45.	6,255,356	May 2001	Jones, III				
46.	6,379,684	Apr. 2002	Lezdey et al.				
47.	6,511,960	Jan. 2003	Lezdey et al.				
48.	2002/0042401	Apr. 2002	Ferguson et al.				
49.	2003/0013772	Jan. 2003	Murphy et al.				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Chetland 7/14/02

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i> PTO FORM 1449	ATTY. DOCKET NO.	APPLICATION NO.
	02486.0073.NPUS01	10/698,072
	APPLICANT Cynthia B. Robinson, et al.	
	FILING DATE	GROUP
	October 29, 2003	1644

<i>W</i>	50.	2003/0138434	Jul. 2003	Campbell et al.				
<i>W</i>	51.	2003/0139331	Jul. 2003	Martin et al.				
FOREIGN PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>W</i>	52.	WO 93/16704		PCT				
<i>W</i>	53.	WO 96/16680		PCT				
<i>W</i>	54.	WO 97/48367		PCT				
<i>W</i>	55.	WO 98/03180		PCT				
<i>W</i>	56.	WO 00/54763		PCT				
<i>W</i>	57.	WO-01/015745		PCT				
<i>W</i>	58.	WO-02/069955		PCT				
<i>W</i>	59.	WO-02/85296		PCT				
<i>W</i>	60.	WO-03/072572		PCT				
<i>W</i>	61.	WO-04/014993 A2		PCT				
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)								
<i>W</i>	62.	Araneo et al., "Dehydroepiandrosterone Reduces Progressive Dermal Ischemia Caused by Thermal Injury", <i>J. Surg. Res.</i> 59(2):250-62 (1995).						
<i>W</i>	63.	Bonnett-et al., "Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension," <i>PNAS</i> 100(16):9488-93 (2003).						
<i>W</i>	64.	Budavari, The Merck Index 11 th ed., 1989, pp. 660-661, monograph 4141.						
<i>W</i>	65.	Coleridge et al., "Intravenous aminophylline confers no benefit in acute asthma treated with intravenous steroids and inhaled bronchodilators", <i>Aust. N.Z. J. Med.</i> 23:348-54 (1993).						
<i>W</i>	66.	Dashtaki et al., "Dehydroepiandrosterone and Analogs Inhibit DNA Binding of AP-1 and Airway Smooth Muscle Proliferation", <i>J. Pharmacol. Exp. Thera.</i> 285(2):876-83 (1998).						
<i>W</i>	67.	Dompeling et al., "Treatment with Inhaled Steroids in Asthma and Chronic Bronchitis: Long Term Compliance and Inhaler Technique", <i>Family Practice</i> 9(2):161-6 (1992).						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i> PTO FORM 1449	ATTY. DOCKET NO. 02486.0073.NPUS01	APPLICATION NO. 10/698.072
	APPLICANT Cynthia B. Robinson, et al.	
	FILING DATE October 29, 2003	GROUP 1644

68.	Dunn, et al., "Dehydroepiandrosterone sulphate concentrations in asthmatic patients: pilot study," <i>N.Z. J. Med.</i> 97(768):805-8 (1984).
69.	Duplantier, et al., Novel pharmacological approaches to the treatment of asthma: status and potential of therapeutic classes", <i>DDT</i> 1(5):199-207 (1996)
70.	Dworski et al., "Conspectus: Inhaled Steroids in Asthma", <i>Comprehensive Therapy</i> , 18:3 (1992).
71.	Fehér et al., "Adrenocortical Function in Bronchial Asthma", <i>Acta Medica Hungarica</i> 40(2-3):125-32 (1983).
72.	Fehér, et al., " Dehydroepiandrosterone Therapy of Patients with Corticosteroid Dependent Bronchial Asthma," <i>Natl. Institute of Rheumatism and Physiotherapy, in XIII Congress of the European Academy of Allergology and Clinical Immunology</i> , eds. (Saba, et al., Debrecen Hungary (1986).
73.	Hampel et al., "Dehydroepiandrosterone sulphate reduces chronic hypoxic pulmonary hypertension in rats," <i>J. Eur. Respir.</i> 21:862-5 (2003).
74.	Holzmann et al., "Therapy of Psoriasis with Dehydroepiandrosterone-Enanthate. II. Intramuscular Depot Application of 300 mg", <i>Arch. Dermatol. Forsch.</i> 247(1):23-8 (1973) (German with English Abstract).
75.	Hummel et al., "Comparison of oral-steroid sparing by high-dose and low-dose inhaled steroid in maintenance treatment of severe asthma", <i>The Lancet</i> , 340(8834/8835):1483-7 (1992).
76.	Itagaki et al., "Effect of Cortisol on the Release of Human Decidual", <i>Caplus</i> , 114875 (1991) (Japanese with English Abstract).
77.	Koó et al., "Our experiences with Dehydroepiandrosterone Therapy in Steroid-Dependent Intrinsic Bronchial Asthma", <i>Orvosi Hetilap</i> 128(38):1995-7 (1987) (Hungarian).
78.	Koó et al., " Our experiences with Dehydroepiandrosterone Therapy in Steroid-Dependent Intrinsic Bronchial Asthma ", <i>Orvosi Hetilap</i> 128(38):1995-7 (1987) (English translation).
79.	Lejeune, "Pathogenesis of Mental Impairment in Trisomy 21", <i>Annales de Génétique</i> , 92:27643 (1996) (French with English Abstract).
80.	Mileva et al., "Androstenedione, DHEA sulfate, cortisol, aldosterone and testosterone in bronchial asthma patients", 07608054 (1990) (Russian with English Abstract).
81.	Nakagawa, et al., "The Properties of Water of Crystallization of Sodium Prasterone Sulfate," <i>Chem. Pharm. Bull</i> 29(5):1466-9 (1981)
82.	Nakagawa, et al., "The Grinding and Drying on the Solid State Stability of Sodium Prasterone Sulfate," <i>Chem. Pharm. Bull</i> 30(1):242-8 (1982)
83.	Pashko et al., "Inhibition of 7,12-dimethylbenz(a)anthracene-induced Skin Papillomas and Carcinomas by Dehydroepiandrosterone and 3-beta-methylandro-5-en-17-one in mice", <i>Cancer Res.</i> 45(1):164-6 (1985).

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p align="center">LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)</p> <p align="center">PTO FORM 1449</p>	ATTY. DOCKET NO. 02486.0073.NPUS01	APPLICATION NO. 10/698,072
	APPLICANT Cynthia B. Robinson, et al.	
	FILING DATE October 29, 2003	GROUP 1644

<input checked="" type="checkbox"/>	84.	Peeters <i>et al.</i> , "Differences in Purine Metabolism in Patients with Down's Syndrome", <i>J. Intellect. Diabil. Res.</i> 37:471 (1993). Abstract.
<input checked="" type="checkbox"/>	85.	Reed, "Aerosol Steroids as Primary Treatment of Mild Asthma", <i>New England J. Med.</i> , 325(6):425-6 (1991).
<input checked="" type="checkbox"/>	86.	Rowe <i>et al.</i> , "Effectiveness of Steroid Therapy in Acute Exacerbations of Asthma: A Meta-analysis", <i>Amer. J. Emergency Med.</i> , 10(4):301-10 (1992).
<input checked="" type="checkbox"/>	87.	Sasaki <i>et al.</i> , "Cervical Ripening with Dehydroepiandrosterone Sulphate", <i>Br. J. Obstet. Gynaecol.</i> 89(3):195-8, (1982).
<input checked="" type="checkbox"/>	88.	Sciarra <i>et al.</i> , "Aerosols", Remington's Pharmaceutical Sciences, 18 th ed. (1990), Eds. Gennaro <i>et al.</i> , pp. 1873-5 and 1694-1712.
<input checked="" type="checkbox"/>	89.	Sharma <i>et al.</i> , "Screening of potential chemopreventive agents using biochemical markers of carcinogenesis", <i>Cancer Res.</i> 54(22):5848-55 (1994).
<input checked="" type="checkbox"/>	90.	Shomali, "The Use of Anti-Aging Hormones. Melatonin. Growth Hormone, Testosterone, and Dehydroepiandrosterone: Consumer Enthusiasm for Unproven Therapies", <i>Md. Med. J.</i> 46(4):181-6 (1997).
<input checked="" type="checkbox"/>	91.	Sonka <i>et al.</i> , "Gout and Dehydroepiandrosterone: 3. DHEA Administration", <i>Endokrynologia Polska</i> 24(3):209-18 (1973).
<input checked="" type="checkbox"/>	92.	Sur <i>et al.</i> , "Double-blind trial pyroxidine (vitamin B6) in the treatment of steroid-dependent asthma", <i>Ann. Allergy</i> , 70:147-52 (1993).
<input checked="" type="checkbox"/>	93.	Schwartz <i>et al.</i> , "Inhibition of 7,12-dimethylbenz[a]anthracene- and urethan-induced lung tumor formation in A/J mice by long-term treatment with dehydroepiandrosterone", <i>Carcinogenesis</i> 2(12):1335-7 (1981)
<input checked="" type="checkbox"/>	94.	Van-de-Graaf <i>et al.</i> , "Respiratory Membrane Permeability and Bronchial Hyperreactivity in Patients with Stable Asthma: Effects of Therapy with Inhaled Steroids", <i>Bronchial Asthma and Respiratory Membrane Permeability</i> 143:362-8 (1991).
<input checked="" type="checkbox"/>	95.	Van Vollenhoven <i>et al.</i> , "Dehydroepiandrosterone in SLE. Results of a Double-Blind, Placebo-Controlled, Randomized Clinical Trial.", <i>Arthritis Rheum.</i> 38(12): 1826-31 (1995).
<input checked="" type="checkbox"/>	96.	Wolkowitz <i>et al.</i> , "Dehydroepiandrosterone Treatment of Depression", <i>Biol. Psychiatry</i> 41(3):311-8. (1997).

Not considered as
the docs are provided
not by the applicant

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.